retatrutide discord and the Rise of the "Triple G" - The Peptide Research Podcast Retatrutide Europe & Test Results

Current Access Pathways in Canada Retatrutide remains in Phase 3 clinical trials with Health Canada approval expected following FDA decisions, typically 6-12 months after U.S

Most people notice increased appetite suppression within one to two weeks of the switch, sometimes with a temporary increase in GI side effects as the body adjusts to the dual agonist

In Q1, it completed the acquisition of YourBio Health, Boston-based pioneer in capillary whole blood sampling technology

Exercise, protein intake, age, and overall nutrition all play major roles

Mechanism of Action Retatrutides multi-receptor activation leads to: Strong suppression of appetite and food intake (GLP-1 & GIP pathways) Enhanced insulin secretion and glucose control Potential increases in energy expenditure and fat oxidation (glucagon agonism, which may uniquely drive liver fat reduction) Early studies suggest additive benefits beyond tirzepatide or semaglutide, but full long-term data are pending